HK1107261A1 - Method of wound healing using a2b adenosine receptor antagonists - Google Patents

Method of wound healing using a2b adenosine receptor antagonists

Info

Publication number
HK1107261A1
HK1107261A1 HK07112965.9A HK07112965A HK1107261A1 HK 1107261 A1 HK1107261 A1 HK 1107261A1 HK 07112965 A HK07112965 A HK 07112965A HK 1107261 A1 HK1107261 A1 HK 1107261A1
Authority
HK
Hong Kong
Prior art keywords
wound healing
receptor antagonists
adenosine receptor
adenosine
antagonists
Prior art date
Application number
HK07112965.9A
Other languages
English (en)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1107261A1 publication Critical patent/HK1107261A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HK07112965.9A 2004-09-01 2007-11-27 Method of wound healing using a2b adenosine receptor antagonists HK1107261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
HK1107261A1 true HK1107261A1 (en) 2008-04-03

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112965.9A HK1107261A1 (en) 2004-09-01 2007-11-27 Method of wound healing using a2b adenosine receptor antagonists

Country Status (22)

Country Link
US (1) US20060058322A1 (sl)
EP (1) EP1789053B1 (sl)
JP (2) JP4929173B2 (sl)
KR (1) KR101247528B1 (sl)
CN (1) CN101043889B (sl)
AU (1) AU2005282860B2 (sl)
CA (1) CA2578702A1 (sl)
DK (1) DK1789053T3 (sl)
ES (1) ES2387653T3 (sl)
HK (1) HK1107261A1 (sl)
HR (1) HRP20120712T1 (sl)
IL (1) IL181634A (sl)
MX (1) MX2007002437A (sl)
NO (1) NO20071718L (sl)
NZ (1) NZ553487A (sl)
PL (1) PL1789053T3 (sl)
PT (1) PT1789053E (sl)
RS (1) RS52455B (sl)
RU (1) RU2385322C2 (sl)
SI (1) SI1789053T1 (sl)
WO (1) WO2006028810A2 (sl)
ZA (1) ZA200701777B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894250B (zh) 2003-08-25 2010-06-09 PGx健康有限责任公司 取代的8-杂芳基黄嘌呤
JP2008516969A (ja) 2004-10-15 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
KR20080016645A (ko) * 2005-06-16 2008-02-21 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제의 프로드러그
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
EP3762386B1 (en) * 2018-03-05 2024-01-24 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU2001238342A1 (en) * 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
IL161867A0 (en) * 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
MXPA06004789A (es) * 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
US20060058322A1 (en) 2006-03-16
WO2006028810A3 (en) 2006-09-28
CA2578702A1 (en) 2006-03-16
HRP20120712T1 (hr) 2012-10-31
RU2385322C2 (ru) 2010-03-27
RU2007107605A (ru) 2008-09-10
CN101043889A (zh) 2007-09-26
IL181634A (en) 2015-05-31
MX2007002437A (es) 2007-08-14
ZA200701777B (en) 2008-09-25
SI1789053T1 (sl) 2012-09-28
PL1789053T3 (pl) 2012-12-31
NO20071718L (no) 2007-03-30
CN101043889B (zh) 2010-11-03
JP2008511654A (ja) 2008-04-17
EP1789053B1 (en) 2012-06-13
AU2005282860B2 (en) 2012-03-22
JP4929173B2 (ja) 2012-05-09
JP2011246492A (ja) 2011-12-08
KR20070047816A (ko) 2007-05-07
ES2387653T3 (es) 2012-09-27
DK1789053T3 (da) 2012-08-06
NZ553487A (en) 2010-09-30
RS52455B (en) 2013-02-28
IL181634A0 (en) 2007-07-04
PT1789053E (pt) 2012-08-09
WO2006028810A2 (en) 2006-03-16
EP1789053A2 (en) 2007-05-30
KR101247528B1 (ko) 2013-04-15
AU2005282860A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
HK1107261A1 (en) Method of wound healing using a2b adenosine receptor antagonists
IL178365A (en) Selective antagonists of a2a adenosine receptors
IL175759A0 (en) A2b adenosine receptor antagonists
IL182493A0 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
TWI346553B (en) Chemokine receptor antagonists
ZA200710878B (en) Prodrugs of A2B adenosine receptor antagonists
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
ZA200703229B (en) Use of A2A adenosine receptor agonists
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
EP1726660A4 (en) METHOD OF MEASURING GLYCOPROTEINS
PL1786744T3 (pl) Sposób opóźniania wiązania gipsu i preparatów gipsowych
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
EP1734966A4 (en) USE OF PIPERAZINYLPIPERIDINE DERIVATIVES AS ANTAGONISTS OF CHEMOKINE RECEPTORS
PL1751175T3 (pl) Antagoniści receptora IL-1, kompozycje i sposoby leczenia
EP2041136A4 (en) SELECTIVE ANTAGONISTS OF ADENOSINE A2A RECEPTORS
EP1750722A4 (en) NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
GB0411123D0 (en) High-affinity NY-ESO T cell receptors
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
ZA200707714B (en) Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
PL383615A1 (pl) Arylindenopirydyny i arylindenopirymidyny oraz ich zastosowanie jako antagonistów receptora adenozynowego A2a
IL182420A0 (en) Crf receptor antagonists and methods relating thereto